Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALANASDAQ:DRRXNASDAQ:KINNASDAQ:MRUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00$0.00▼$0.05N/A-2.8213,914 shs5 shsDRRXDURECT$0.67+0.0%$0.61$0.48▼$1.74$20.70M0.6442,459 shs16,699 shsKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsMRUSMerus$53.84+1.0%$49.89$33.19▼$62.98$3.73B1738,077 shs222,443 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%0.00%-95.00%-83.33%-99.00%DRRXDURECT0.00%+6.47%+15.35%-14.83%-47.91%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%MRUSMerus0.00%+1.60%-6.50%+41.28%+1.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALACalithera Biosciences0.6395 of 5 stars0.01.00.04.50.60.00.0DRRXDURECT0.5473 of 5 stars0.02.00.04.41.10.00.0KINKindred BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AMRUSMerus1.8603 of 5 stars3.61.00.00.01.42.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera Biosciences 0.00N/AN/AN/ADRRXDURECT 2.00HoldN/AN/AKINKindred Biosciences 0.00N/AN/AN/AMRUSMerus 3.14Buy$84.6457.20% UpsideCurrent Analyst Ratings BreakdownLatest DRRX, CALA, KIN, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/19/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.005/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.004/28/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/9/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$83.00 ➝ $83.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera BiosciencesN/AN/AN/AN/AN/AN/ADRRXDURECT$2.03M10.19N/AN/A$0.29 per share2.30KINKindred Biosciences$42.16M9.97N/AN/A$1.75 per share5.29MRUSMerus$36.13M103.13N/AN/A$9.46 per share5.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/A0.00N/AN/AN/AN/AN/AN/ADRRXDURECT-$8.32M-$0.15N/AN/AN/A-91.54%-267.36%-64.00%8/12/2025 (Estimated)KINKindred Biosciences-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/AMRUSMerus-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)Latest DRRX, CALA, KIN, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/ADRRXDURECTN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALACalithera BiosciencesN/AN/AN/ADRRXDURECTN/A1.231.22KINKindred Biosciences0.197.027.02MRUSMerusN/A5.865.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/ADRRXDURECT28.03%KINKindred Biosciences66.89%MRUSMerus96.14%Insider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%DRRXDURECT3.20%KINKindred Biosciences13.69%MRUSMerus4.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableDRRXDURECT8031.04 million30.05 millionOptionableKINKindred Biosciences6345.46 millionN/AOptionableMRUSMerus3769.21 million66.05 millionOptionableDRRX, CALA, KIN, and MRUS HeadlinesRecent News About These CompaniesMoody Aldrich Partners LLC Has $4.56 Million Holdings in Merus N.V. (NASDAQ:MRUS)July 4 at 6:43 AM | marketbeat.comStocks To Watch: Merus Sees RS Rating Rise To 84July 2 at 2:22 PM | msn.comMerus N.V.: Making ProgressJune 29, 2025 | seekingalpha.comMerus N.V. (MRUS) Latest Stock News & Headlines - Yahoo FinanceJune 26, 2025 | finance.yahoo.comStocks Showing Rising Market Leadership: Merus Earns 81 RS RatingJune 25, 2025 | msn.comMerus N.V. (NASDAQ:MRUS) COO Sells $1,793,840.00 in StockJune 25, 2025 | insidertrades.comPeter B. Silverman Sells 34,000 Shares of Merus N.V. (NASDAQ:MRUS) StockJune 24, 2025 | marketbeat.comMerus N.V. (NASDAQ:MRUS) Given Average Recommendation of "Buy" by BrokeragesJune 21, 2025 | marketbeat.comNet Worth Advisory Group Buys Shares of 5,054 Merus (NASDAQ:MRUS)June 14, 2025 | marketbeat.comHarbor Capital Advisors Inc. Has $2.71 Million Stake in Merus (NASDAQ:MRUS)June 12, 2025 | marketbeat.comBicara Therapeutics Looks To Reclaim Some Of The Spotlight From MerusJune 11, 2025 | seekingalpha.comMerus’s Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price TargetJune 10, 2025 | tipranks.comUnderappreciated Potential of Merus’s Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial StabilityJune 9, 2025 | tipranks.comWhy Merus N.V. (MRUS) Crashed On WednesdayJune 5, 2025 | msn.comWhy Merus N.V. (MRUS) Crashed On WednesdayJune 5, 2025 | insidermonkey.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 14,544 Shares of Merus (NASDAQ:MRUS)June 5, 2025 | marketbeat.comBank of America Corp DE Has $1.59 Million Stock Position in Merus (NASDAQ:MRUS)June 5, 2025 | marketbeat.comMerus Shares Slide on Stock OfferingJune 4, 2025 | marketwatch.comMerus N.V. Announces Pricing of $300 Million Public Offering of Common SharesJune 3, 2025 | quiverquant.comQMerus N.V. Announces Pricing of Public Offering of Common SharesJune 3, 2025 | globenewswire.comMerus NV Announces Proposed Public Offering of Common Shares | MRUS stock newsJune 3, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseWhy Goldman Sachs Suddenly Boosted These 3 Trucking StocksBy Gabriel Osorio-Mazilli | June 9, 2025View Why Goldman Sachs Suddenly Boosted These 3 Trucking Stocks3 Stocks With Near-Unanimous Buys That Could Rally HigherBy Nathan Reiff | July 2, 2025View 3 Stocks With Near-Unanimous Buys That Could Rally HigherDRRX, CALA, KIN, and MRUS Company DescriptionsCalithera Biosciences NASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.DURECT NASDAQ:DRRX$0.67 +0.00 (+0.02%) As of 07/3/2025 01:00 PM EasternDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Kindred Biosciences NASDAQ:KINKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.Merus NASDAQ:MRUS$53.84 +0.51 (+0.96%) Closing price 07/3/2025 01:04 PM EasternExtended Trading$53.38 -0.46 (-0.85%) As of 07/3/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
